This is a routine board refresh with no operational or strategic implications. The compensation is standard for a biotech firm of this size. Traders should monitor for any future insider transactions or additional governance changes.
Price Chart
Executive Summary
Xilio Therapeutics appointed Cheryl R. Blanchard, Ph.D., to its Board of Directors and Compensation Committee chair, succeeding Christina Rossi who resigned. The company also disclosed standard non-employee director compensation terms, including cash retainers and stock options.
Key Facts
- Cheryl R. Blanchard, Ph.D., was elected to the Board of Directors and appointed chair of the Compensation Committee and member of the Audit Committee.
- Christina Rossi resigned from the Board and all committees effective April 15, 2026, with no disagreement cited.
- Dr. Blanchard will receive $40,000 annual cash fee for Board service, $12,000 as Compensation Committee chair, and $7,500 as Audit Committee member.
- She will receive an initial stock option grant for 10,000 shares vesting annually over three years and annual grants of 5,000 shares after six months of service.
- The company filed its Amended and Restated Non-Employee Director Compensation Policy.
Financial Impact
Approximately $59,500 annual cash compensation and equity grants valued at current market price for Dr. Blanchard's service.
Risk Factors
- Potential for increased share dilution from ongoing equity grants to directors.
- Board stability risk if additional members depart following Rossi's resignation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-157940 |
| Document: xlo-ex10_1.htm | 0001193125-26-157940 |
| Document: 0001193125-26-157940-index-headers.html | 0001193125-26-157940 |
| Document: 0001193125-26-157940-index.html | 0001193125-26-157940 |
| Document: 0001193125-26-157940.txt | 0001193125-26-157940 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | — | awaiting T+5 | — | — |
Aug 12, 2026 10w ago | 8-K | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $8.16 (−9.81%) |
Aug 12, 2026 10w ago | Press Release | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $8.16 (−9.81%) |
Jun 1, 2026 21w ago | EFFECT | $8.25 $7.70 | ▲ +6.67% | ▲ +3.92% | $8.16 (+1.06%) |
May 27, 2026 21w ago | S-3/A | $8.52 $8.15 | ▼ −4.40% | ▼ −4.35% | $8.16 (−4.20%) |
May 12, 2026 23w ago | 8-K | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.16 (+5.60%) |
May 12, 2026 23w ago | Press Release | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.16 (+5.60%) |
Apr 17, 2026 27w ago | Press Release | $8.45 $8.18 | ▼ −3.20% | ▼ −4.11% | $8.16 (−3.40%) |
Apr 16, 2026 27w ago | 3 | $8.57 $8.31 | ▼ −3.03% | ▼ −3.59% | $8.16 (−4.75%) |
Apr 16, 2026 27w ago | 8-K | $8.35 $8.47 | ▲ +1.44% | ▲ +0.45% | $8.16 (−2.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers